EA200100010A1 - Местное применение оксазолидинонов для трансдермальной доставки - Google Patents

Местное применение оксазолидинонов для трансдермальной доставки

Info

Publication number
EA200100010A1
EA200100010A1 EA200100010A EA200100010A EA200100010A1 EA 200100010 A1 EA200100010 A1 EA 200100010A1 EA 200100010 A EA200100010 A EA 200100010A EA 200100010 A EA200100010 A EA 200100010A EA 200100010 A1 EA200100010 A1 EA 200100010A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxazolidinones
transdermal delivery
local application
infections
bacteremia
Prior art date
Application number
EA200100010A
Other languages
English (en)
Other versions
EA003699B1 (ru
Inventor
Чарльз В. Форд
Джеффри Л. Ваттс
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of EA200100010A1 publication Critical patent/EA200100010A1/ru
Publication of EA003699B1 publication Critical patent/EA003699B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Раскрывается способ лечения нелокальной инфекции, выбираемой из группы, состоящей из ушных инфекций, инфекций кожи и мягких тканей, акне, инфицированных ран, бактериемии у полезных теплокровных млекопитающих, нуждающихся в таком лечении, включающее в себя местное применение фармацевтической композиции, содержащей трансдермально эффективное количество оксазолидинона.Отчет о международном поиске был опубликован 2000.02.24.
EA200100010A 1998-06-05 1999-05-26 Способ лечения бактериальной инфекции и фармацевтическая композиция для его осуществления EA003699B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8828398P 1998-06-05 1998-06-05
PCT/US1999/010463 WO1999062504A2 (en) 1998-06-05 1999-05-26 Topical administration of oxazolidinones for transdermal delivery

Publications (2)

Publication Number Publication Date
EA200100010A1 true EA200100010A1 (ru) 2001-06-25
EA003699B1 EA003699B1 (ru) 2003-08-28

Family

ID=22210475

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100010A EA003699B1 (ru) 1998-06-05 1999-05-26 Способ лечения бактериальной инфекции и фармацевтическая композиция для его осуществления

Country Status (29)

Country Link
US (2) US6613349B2 (ru)
EP (1) EP1083900B1 (ru)
JP (1) JP2002516852A (ru)
KR (1) KR100626781B1 (ru)
CN (1) CN1168447C (ru)
AT (1) ATE220548T1 (ru)
AU (1) AU749523B2 (ru)
BR (1) BR9910318A (ru)
CA (1) CA2327326A1 (ru)
CO (1) CO5011042A1 (ru)
CZ (1) CZ292420B6 (ru)
DE (1) DE69902170T2 (ru)
DK (1) DK1083900T3 (ru)
EA (1) EA003699B1 (ru)
ES (1) ES2179658T3 (ru)
HK (1) HK1036593A1 (ru)
HU (1) HU225234B1 (ru)
ID (1) ID23775A (ru)
IL (1) IL139843A0 (ru)
MY (1) MY122454A (ru)
NO (1) NO20006161D0 (ru)
NZ (1) NZ508636A (ru)
PL (1) PL193535B1 (ru)
PT (1) PT1083900E (ru)
SK (1) SK285352B6 (ru)
TR (1) TR200003205T2 (ru)
TW (1) TWI224000B (ru)
WO (1) WO1999062504A2 (ru)
ZA (1) ZA200005886B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112409285A (zh) * 2020-11-30 2021-02-26 山东金城昆仑药业有限公司 噁唑烷酮类化合物的晶型及其制备方法和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562820B2 (en) * 2000-07-05 2003-05-13 Pharmacia & Upjohn Company Method for treatment and prevention of mastitis
US20030096850A1 (en) * 2001-10-11 2003-05-22 Ford Charles W. Treating infections by administration of oxazolidinones
PL372661A1 (en) * 2002-03-29 2005-07-25 Pharmacia & Upjohn Company Llc. Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743727A (en) 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4507287A (en) 1983-06-20 1985-03-26 Dixon Glen J Preparation and method for the treatment of acne
JP2558107B2 (ja) 1986-12-18 1996-11-27 第一製薬株式会社 外用剤
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4960771A (en) * 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5164510A (en) 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
KR100257418B1 (ko) 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
TW203552B (en) * 1992-02-18 1993-04-11 J Baroody Lloyd Compositions of clindamycin and benzoyl peroxide for acne treatment
US5457194A (en) * 1993-03-17 1995-10-10 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
ATE182142T1 (de) 1993-11-22 1999-07-15 Upjohn Co Substituierte hydroxyacetyl piperazine phenyl oxazolidinonsäureester
DE4425612A1 (de) 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425613A1 (de) 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
PT781122E (pt) 1994-09-14 2000-11-30 Minnesota Mining & Mfg Matriz para a distribuicao transdermica de farmacos
US5604262A (en) * 1995-03-22 1997-02-18 Research Corporation Technologies, Inc. Topical antimicrobial agents
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
ATE229805T1 (de) 1996-05-10 2003-01-15 Upjohn Co Topische verabreichung von premafloxacin zur behandlung von systemischen bakteriellen erkrankungen
US5929086A (en) * 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
US6040306A (en) * 1997-11-18 2000-03-21 Pharmacia & Upjohn Company Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
US6312715B1 (en) 1998-05-01 2001-11-06 3M Innovative Properties Company Adhesive microsphere drug delivery composition
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112409285A (zh) * 2020-11-30 2021-02-26 山东金城昆仑药业有限公司 噁唑烷酮类化合物的晶型及其制备方法和应用

Also Published As

Publication number Publication date
AU4184899A (en) 1999-12-20
ID23775A (id) 2000-05-11
HU225234B1 (en) 2006-08-28
SK285352B6 (sk) 2006-11-03
TR200003205T2 (tr) 2001-05-21
US7892574B2 (en) 2011-02-22
NZ508636A (en) 2002-03-01
HK1036593A1 (en) 2002-01-11
CO5011042A1 (es) 2001-02-28
WO1999062504A2 (en) 1999-12-09
CA2327326A1 (en) 1999-12-09
CN1168447C (zh) 2004-09-29
NO20006161L (no) 2000-12-04
DK1083900T3 (da) 2002-11-04
SK16262000A3 (sk) 2001-06-11
PL345119A1 (en) 2001-12-03
PL193535B1 (pl) 2007-02-28
CZ292420B6 (cs) 2003-09-17
DE69902170D1 (de) 2002-08-22
KR100626781B1 (ko) 2006-09-22
MY122454A (en) 2006-04-29
ZA200005886B (en) 2002-04-22
NO20006161D0 (no) 2000-12-04
ES2179658T3 (es) 2003-01-16
EP1083900A2 (en) 2001-03-21
KR20010052555A (ko) 2001-06-25
CN1298302A (zh) 2001-06-06
US6613349B2 (en) 2003-09-02
HUP0102191A2 (hu) 2002-05-29
US20020009483A1 (en) 2002-01-24
IL139843A0 (en) 2002-02-10
ATE220548T1 (de) 2002-08-15
JP2002516852A (ja) 2002-06-11
HUP0102191A3 (en) 2003-07-28
DE69902170T2 (de) 2003-03-13
WO1999062504A3 (en) 2000-02-24
US20040072841A1 (en) 2004-04-15
BR9910318A (pt) 2001-01-30
AU749523B2 (en) 2002-06-27
PT1083900E (pt) 2002-12-31
CZ20004432A3 (cs) 2001-03-14
TWI224000B (en) 2004-11-21
EP1083900B1 (en) 2002-07-17
EA003699B1 (ru) 2003-08-28

Similar Documents

Publication Publication Date Title
NO20004282D0 (no) Matriksproteinpreparater for sÕrheling
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
BR9406059A (pt) Composição farmacéutica e método para tratamento de uma infecção helmintica em um animal
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
WO2000012049A3 (en) A method for the treatment of staphylococcal disease
EA200100010A1 (ru) Местное применение оксазолидинонов для трансдермальной доставки
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
ATE304886T1 (de) Oxazolidinones zur behandlung von augeninfektionen
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
DE69729201D1 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
KR970704442A (ko) 일시적인 병소 허혈에 의해 유발된 재관류 손상을 치료하기 위한 (S)-아데노실-L-메티오닌(SAMe) 및 그의 생리학상 적합한 염의 용도(Use of (S)-Adenosy-L-Methionine(SAMe) and lts Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
ATE238286T1 (de) Neue triazole als therapeutische mittel gegen pilzinfektionen
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
ECSP992967A (es) Aplicación topica de oxazolidinonas para administracion transdermica
EA200101171A1 (ru) Способ лечения инфекций, вызванных streptococcus pneumoniae
TH57851B (th) การให้ออกซาโซลิดิโนนเฉพาะที่สำหรับการส่งผ่านทางผิวหนัง
MX9605312A (es) Dipsipeptidos ciclicos antifungales.
CO4810229A1 (es) Composicion veterinaria oral que contiene un agente antibac- terial de fluoroquinolona con superiores propiedades de absorcion y duracion extendida de niveles de sangre antimi- crobial terapeutica y metodo de tratamiento

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU